Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington's disease human brain.

Patassini S, Begley P, Xu J, Church SJ, Reid SJ, Kim EH, Curtis MA, Dragunow M, Waldvogel HJ, Snell RG, Unwin RD, Faull RL, Cooper GJ.

Biochim Biophys Acta. 2016 Sep;1862(9):1650-62. doi: 10.1016/j.bbadis.2016.06.002. Epub 2016 Jun 4.

2.

Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington's disease.

Patassini S, Begley P, Reid SJ, Xu J, Church SJ, Curtis M, Dragunow M, Waldvogel HJ, Unwin RD, Snell RG, Faull RL, Cooper GJ.

Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):161-6. doi: 10.1016/j.bbrc.2015.10.140. Epub 2015 Oct 30.

PMID:
26522227
3.

Metabolic signatures of Huntington's disease (HD): (1)H NMR analysis of the polar metabolome in post-mortem human brain.

Graham SF, Kumar PK, Bjorndahl T, Han B, Yilmaz A, Sherman E, Bahado-Singh RO, Wishart D, Mann D, Green BD.

Biochim Biophys Acta. 2016 Sep;1862(9):1675-84. doi: 10.1016/j.bbadis.2016.06.007. Epub 2016 Jun 8.

4.
5.

Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.

Handley RR, Reid SJ, Brauning R, Maclean P, Mears ER, Fourie I, Patassini S, Cooper GJS, Rudiger SR, McLaughlan CJ, Verma PJ, Gusella JF, MacDonald ME, Waldvogel HJ, Bawden CS, Faull RLM, Snell RG.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11293-E11302. doi: 10.1073/pnas.1711243115. Epub 2017 Dec 11.

6.

Metabolic disruption identified in the Huntington's disease transgenic sheep model.

Handley RR, Reid SJ, Patassini S, Rudiger SR, Obolonkin V, McLaughlan CJ, Jacobsen JC, Gusella JF, MacDonald ME, Waldvogel HJ, Bawden CS, Faull RL, Snell RG.

Sci Rep. 2016 Feb 11;6:20681. doi: 10.1038/srep20681.

7.

Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.

Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM.

Cell Death Differ. 2004 Apr;11(4):424-38.

8.

Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.

Chang KL, New LS, Mal M, Goh CW, Aw CC, Browne ER, Chan EC.

J Proteome Res. 2011 Apr 1;10(4):2079-87. doi: 10.1021/pr2000336. Epub 2011 Mar 16.

PMID:
21355552
9.

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA.

Cell Cycle. 2015;14(11):1716-29. doi: 10.1080/15384101.2015.1033595.

10.

Targeted biochemical profiling of brain from Huntington's disease patients reveals novel metabolic pathways of interest.

Graham SF, Pan X, Yilmaz A, Macias S, Robinson A, Mann D, Green BD.

Biochim Biophys Acta Mol Basis Dis. 2018 Jul;1864(7):2430-2437. doi: 10.1016/j.bbadis.2018.04.012. Epub 2018 Apr 21.

PMID:
29684586
11.

Oxidative damage in Huntington's disease pathogenesis.

Browne SE, Beal MF.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2061-73. Review.

PMID:
17034350
12.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1939-51.

PMID:
12165556
13.

Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR.

J Neurosci. 2002 Sep 15;22(18):7862-72.

14.

Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.

Liu W, Chaurette J, Pfister EL, Kennington LA, Chase KO, Bullock J, Vonsattel JP, Faull RL, Macdonald D, DiFiglia M, Zamore PD, Aronin N.

J Huntingtons Dis. 2013;2(4):491-500. doi: 10.3233/JHD-130079.

PMID:
25062733
15.

Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.

Heikkinen T, Lehtimäki K, Vartiainen N, Puoliväli J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjänheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC.

PLoS One. 2012;7(12):e50717. doi: 10.1371/journal.pone.0050717. Epub 2012 Dec 20.

16.

NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington's Disease Suggests Altered Cell Energetics.

Singh V, Sharma RK, Athilingam T, Sinha P, Sinha N, Thakur AK.

J Proteome Res. 2017 Oct 6;16(10):3863-3872. doi: 10.1021/acs.jproteome.7b00491. Epub 2017 Sep 26.

PMID:
28871787
17.
18.

Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains.

Ratovitski T, Chaerkady R, Kammers K, Stewart JC, Zavala A, Pletnikova O, Troncoso JC, Rudnicki DD, Margolis RL, Cole RN, Ross CA.

J Proteome Res. 2016 Sep 2;15(9):3266-83. doi: 10.1021/acs.jproteome.6b00448. Epub 2016 Aug 3.

19.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.

20.

Evidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue.

Kreilaus F, Spiro AS, McLean CA, Garner B, Jenner AM.

Neuropathol Appl Neurobiol. 2016 Oct;42(6):535-46. doi: 10.1111/nan.12286. Epub 2015 Oct 15.

PMID:
26373857

Supplemental Content

Support Center